Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
This is a chart review of 200 Xofigo patients to describe sequencing and characterize clinical parameters and patient determinants that drive physician decision making.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart.
Patients were at least 18 years of age as of the first diagnosis for mCRPC.
Patients must have received at least one intravenous injection of Radium-223 (Xofigo).
First injection of Radium-223 must have started between periods
1-January-2014 to 30-June-2014 or 15-November-2014 to present.
Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.
You may not be if
Patients who received Radium-223 as part in an interventional clinical trial
Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.
Clareo Health | Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
